Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin

Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

(2013) Sameer Doshi et al.   CLINICAL PHARMACOKINETICS

Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

(2013) Karl Swedberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial

(2013) Valentina Forni et al.   BMC Nephrology

Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Patients With Non–Dialysis-Dependent CKD

(2012) Sherrie L. Aspinall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

An expert opinion on the current treatment of anemia in patients with kidney disease

(2012) Francesco Locatelli et al.   EXPERT OPINION ON PHARMACOTHERAPY

Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients

(2012) Roberto Minutolo et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

(2011) M. Untch et al.   ANNALS OF ONCOLOGY

Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa

(2011) Hicham Skali et al.   CIRCULATION

Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction

(2011) Samer S. Najjar   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes

(2011) Yi Zhang et al.   KIDNEY INTERNATIONAL

Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease

(2011) Stephen L. Seliger et al.   KIDNEY INTERNATIONAL

Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease

(2011) Oluwatoyin F. Bamgbola   KIDNEY INTERNATIONAL

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

(2011) J.-C. Galle et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Antibiotic Pharmacokinetic and Pharmacodynamic Considerations in Patients With Kidney Disease

(2010) Rachel F. Eyler et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Exposure-Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis

(2010) Sameer Doshi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

(2010) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erythropoiesis-Stimulating Agents — Time for a Reevaluation

(2010) Ellis F. Unger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients

(2009) CHAN-DUCK KIM et al.   NEPHROLOGY

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response

(2008) M. Brines et al.   JOURNAL OF INTERNAL MEDICINE

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

(2008) Lynda A. Szczech et al.   KIDNEY INTERNATIONAL

The effect of epoetin dose on hematocrit

(2007) D. Cotter et al.   KIDNEY INTERNATIONAL